[go: up one dir, main page]

DE60011446D1 - Substituierte pyridino pentaazamakrozykle komplexe mit superoxid-dismutase-aktivität - Google Patents

Substituierte pyridino pentaazamakrozykle komplexe mit superoxid-dismutase-aktivität

Info

Publication number
DE60011446D1
DE60011446D1 DE60011446T DE60011446T DE60011446D1 DE 60011446 D1 DE60011446 D1 DE 60011446D1 DE 60011446 T DE60011446 T DE 60011446T DE 60011446 T DE60011446 T DE 60011446T DE 60011446 D1 DE60011446 D1 DE 60011446D1
Authority
DE
Germany
Prior art keywords
superoxide dismutase
dismutase activity
pentaaza macrocycle
substituted pyridino
macrocycle complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60011446T
Other languages
English (en)
Other versions
DE60011446T2 (de
Inventor
Dennis Riley
William L Neumann
Susan L Henke
Patrick Lennon
Karl W Aston
Daniela Salvemini
James A Sikorski
Yvette Fobian
Margaret L Grapperhaus
Carrie L Kusturin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monsanto Co
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Publication of DE60011446D1 publication Critical patent/DE60011446D1/de
Application granted granted Critical
Publication of DE60011446T2 publication Critical patent/DE60011446T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60011446T 1999-09-16 2000-09-14 Substituierte Pyridinopentaazamakrocyclokomplexe mit Superoxiddismutaseaktivität Expired - Lifetime DE60011446T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US398120 1999-09-16
US09/398,120 US6214817B1 (en) 1997-06-20 1999-09-16 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
PCT/US2000/025154 WO2001019823A2 (en) 1999-09-16 2000-09-14 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity

Publications (2)

Publication Number Publication Date
DE60011446D1 true DE60011446D1 (de) 2004-07-15
DE60011446T2 DE60011446T2 (de) 2005-07-07

Family

ID=23574065

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60035724T Expired - Lifetime DE60035724T2 (de) 1999-09-16 2000-09-14 Substituierte Pyridino pentaazamakrozyklische Liganden
DE60035440T Expired - Lifetime DE60035440T2 (de) 1999-09-16 2000-09-14 Verwendung von substituierten Pyridinopentaazamakrozyklen-Komplexen mit Superoxiddismutaseaktivität
DE60011446T Expired - Lifetime DE60011446T2 (de) 1999-09-16 2000-09-14 Substituierte Pyridinopentaazamakrocyclokomplexe mit Superoxiddismutaseaktivität

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE60035724T Expired - Lifetime DE60035724T2 (de) 1999-09-16 2000-09-14 Substituierte Pyridino pentaazamakrozyklische Liganden
DE60035440T Expired - Lifetime DE60035440T2 (de) 1999-09-16 2000-09-14 Verwendung von substituierten Pyridinopentaazamakrozyklen-Komplexen mit Superoxiddismutaseaktivität

Country Status (12)

Country Link
US (1) US6214817B1 (de)
EP (3) EP1420022B1 (de)
JP (2) JP2003509423A (de)
AT (3) ATE368039T1 (de)
AU (1) AU784078B2 (de)
CA (1) CA2382105C (de)
DE (3) DE60035724T2 (de)
DK (1) DK1212323T3 (de)
ES (3) ES2222925T3 (de)
HK (1) HK1046689B (de)
PT (1) PT1212323E (de)
WO (1) WO2001019823A2 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
CA2229781A1 (en) * 1995-08-17 1997-02-27 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
US20050171198A1 (en) * 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
JP2001521939A (ja) 1997-11-03 2001-11-13 デューク・ユニバーシティー 置換されたポルフィリン類
NZ513164A (en) 1999-01-25 2006-03-31 Nat Jewish Med & Res Center Substituted porphyrins
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
WO2002053142A2 (en) * 2001-01-05 2002-07-11 Metaphore Pharmaceuticals, Inc. Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
EP1392328B1 (de) 2001-01-19 2009-08-12 National Jewish Medical and Research Center Medikament zum schutz in der radiotherapie
AU2002236861A1 (en) * 2001-01-26 2002-08-06 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20040137638A1 (en) * 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
JP4369124B2 (ja) * 2001-03-02 2009-11-18 メタファー・ファーマシューティカルズ・インコーポレイテッド 金属錯体のクロマトグラフィー
WO2002098431A1 (en) * 2001-06-01 2002-12-12 National Jewish Medical And Research Center Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
AU2002315001A1 (en) * 2001-06-08 2002-12-23 Metaphore Pharmaceuticals, Inc. Libraries of conformationally constrained peptides, chiral azacrowns, and peptidomimetics and methods of making the same
EP1412360A4 (de) * 2001-06-26 2004-07-07 Metaphore Pharmaceuticals Inc KOMBINATIONSTHERAPIE MIT EINEM SODm UND EINEM KORTIKOSTEROID ZUR PRÄVENTION UND/ODER BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN
US20040132706A1 (en) * 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
WO2003051458A1 (en) * 2001-12-14 2003-06-26 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
WO2003103680A1 (en) * 2002-06-07 2003-12-18 Duke University Substituted porphyrins
US6835387B2 (en) 2002-06-11 2004-12-28 Scimed Life Systems, Inc. Sustained release of superoxide dismutase mimics from implantable or insertable medical devices
US20030232784A1 (en) * 2002-06-14 2003-12-18 Benedict James J. Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
US6984636B2 (en) * 2002-08-12 2006-01-10 Medical Research Council Mitochondrially targeted antioxidants
AU2003286389A1 (en) * 2002-11-29 2004-06-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and nitricoxid-donor activity
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
CA2505608A1 (en) * 2002-12-06 2004-06-24 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
EP1691815A4 (de) * 2003-12-11 2010-03-31 Alcon Inc Superoxid-dismutase-mimetika zur behandlung von optikus- und retinaschäden
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) * 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US8217166B2 (en) * 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
US20120301403A1 (en) 2007-06-21 2012-11-29 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
KR100724586B1 (ko) 2005-12-09 2007-06-04 세종대학교산학협력단 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
SI2056675T1 (sl) 2006-10-12 2019-08-30 Galera Labs, Llc Postopki za zdravljenje oralnega mukozitisa
WO2008114017A2 (en) * 2007-03-19 2008-09-25 Imperial Innovations Limited Compositions and methods relating to influenza infection
EP2296645B1 (de) 2008-05-22 2014-11-19 Galera Therapeutics, LLC Antitumorale kombinationstherapie
ES2600469T3 (es) 2008-05-23 2017-02-09 National Jewish Health Un compuesto para su uso en el tratamiento de lesiones asociadas con la exposición al gas fosgeno o al gas de cloro
EP2966108B1 (de) 2008-08-22 2021-03-31 Saudi Aramco Technologies Company Katalysatoren und verfahren zur synthese von polymeren
WO2010077911A1 (en) * 2008-12-17 2010-07-08 Altheus Therapeutics, Inc. Enema formulations
CA2849456C (en) * 2011-09-26 2021-12-07 Galera Therapeutics, Llc Methods for treatment of diseases
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
PE20181519A1 (es) 2011-12-28 2018-09-21 Global Blood Therapeutics Inc Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
JP6463327B2 (ja) 2013-03-15 2019-01-30 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
BR112015021985B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos ou sais farmaceuticamente aceitáveis dos mesmos, respectivos usos e composição
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EP3089666B1 (de) 2013-12-31 2020-08-19 Abbott Diabetes Care Inc. Selbstangetriebener analytsensor und vorrichtungen damit
JP6809681B2 (ja) 2014-02-07 2021-01-06 グローバル ブラッド セラピューティクス インコーポレイテッド ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
LT3334744T (lt) 2015-08-11 2020-07-27 Galera Labs, Llc Pentaaza makrociklinio žiedo kompleksai, turintys peroralinį biologinį prieinamumą
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CA3022699A1 (en) 2016-05-03 2017-11-09 Galera Labs, Llc Combination therapy for cancer treatment
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
AU2017318718B2 (en) * 2016-09-01 2023-06-29 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US20210361701A1 (en) 2017-02-15 2021-11-25 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local delivery
BR112019021393A2 (pt) * 2017-04-13 2020-04-28 Galera Labs Llc imunoterapia combinada contra o câncer com o complexo de anel macrocíclico penta-aza
IL269915B (en) 2017-04-13 2022-09-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex
CN111902147A (zh) 2018-01-31 2020-11-06 加莱拉实验室有限责任公司 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗
TWI710371B (zh) * 2018-05-10 2020-11-21 國立臺灣師範大學 鎳錯合物用於製備緩解膀胱發炎的藥物之用途
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
WO2020163689A1 (en) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors
US20230113847A1 (en) * 2020-03-24 2023-04-13 C Lab Pharma International, S.A. Modulating an immune response with cuprous complexes
CN115260178B (zh) * 2022-08-09 2024-09-20 上海师范大学 一种吡啶骨架ncn噁唑啉类配体的合成方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
NO149961C (no) 1981-06-01 1984-07-25 Borregaard Ind Fremgangsmaate for fremstilling av n-(2-hydroksyetyl)-derivater av makrocykliske polyaminer, inneholdende flere nitrogenatomer i 1,4-forhold i ringen
JPS61226751A (ja) 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US4968616A (en) 1986-05-16 1990-11-06 Masayasu Inoue Superoxide dismutase derivatives, method of producing same and medicinal use of same
US5096724A (en) 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
US5252720A (en) 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
WO1991010669A1 (en) 1990-01-19 1991-07-25 Cockbain, Julian, Roderick, Michaelson Chelating compounds
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
GB9024208D0 (en) 1990-11-07 1990-12-19 Salutar Inc Compounds
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
EP0598753B1 (de) 1991-07-19 1998-03-18 Monsanto Company Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren.
DE69230970T2 (de) 1991-12-10 2001-01-04 The Dow Chemical Co., Midland Bicylclische, polyazamakrocyclocarbonsäure-komplexe, konjugate, herstellung und verwendung als kontraststoffe
US5403834A (en) 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5834509A (en) 1992-12-07 1998-11-10 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5696109A (en) 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
BR9507477A (pt) 1994-04-22 1997-09-16 Searle & Co Métodos de análise de imagem de diagnóstico usando complexos metálicos de ligantes macrocíclicos contendo nitrogênio
WO1996039409A1 (en) 1995-06-05 1996-12-12 Nitromed, Inc. Nitrosylated and nitrated superoxide oxidants and reductants
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1996040658A1 (en) 1995-06-07 1996-12-19 Monsanto Company Process for preparing substituted polyazamacrocycles
SE509595C2 (sv) * 1996-01-25 1999-02-15 Sandvik Ab Skär för spånavskiljande metallbearbetning
CZ271198A3 (cs) * 1996-03-13 1999-01-13 Monsanto Company Biokonjugáty manganu nebo komplexy železa makrocyklických ligandů obsahujících dusík, působící jako katalyzátory pro dismutaci superoxidu
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Also Published As

Publication number Publication date
EP1420022A1 (de) 2004-05-19
EP1212323B1 (de) 2004-06-09
EP1420019B1 (de) 2007-07-25
US6214817B1 (en) 2001-04-10
AU7702400A (en) 2001-04-17
WO2001019823A2 (en) 2001-03-22
PT1212323E (pt) 2004-10-29
AU784078B2 (en) 2006-02-02
CA2382105A1 (en) 2001-03-22
ES2222925T3 (es) 2005-02-16
HK1046689B (en) 2005-03-11
EP1420019A1 (de) 2004-05-19
ES2291759T3 (es) 2008-03-01
ES2293106T3 (es) 2008-03-16
WO2001019823A3 (en) 2001-09-07
EP1420022B1 (de) 2007-07-04
HK1046689A1 (en) 2003-01-24
ATE368039T1 (de) 2007-08-15
EP1212323A2 (de) 2002-06-12
DE60011446T2 (de) 2005-07-07
DE60035440T2 (de) 2008-03-13
DE60035724D1 (de) 2007-09-06
ATE366254T1 (de) 2007-07-15
JP2012097097A (ja) 2012-05-24
CA2382105C (en) 2012-01-10
DE60035724T2 (de) 2008-04-30
ATE268774T1 (de) 2004-06-15
DE60035440D1 (de) 2007-08-16
JP2003509423A (ja) 2003-03-11
WO2001019823A9 (en) 2002-09-26
DK1212323T3 (da) 2004-10-25

Similar Documents

Publication Publication Date Title
DE60011446D1 (de) Substituierte pyridino pentaazamakrozykle komplexe mit superoxid-dismutase-aktivität
AU2002360982A1 (en) Support-fixed bleaching catalyst complex compounds suitable as catalysts for peroxide compounds
ATE511222T1 (de) Komplex der formel l2irx
AU6023796A (en) Manganese or iron complexes of nitrogen-containing macrocycl ic ligands effective as catalysts for dismutating superoxide
PL356486A1 (en) Catalysts for hydrosilylation reactions
EA200500607A1 (ru) Рутениевые комплексы в качестве (пред)катализаторов для реакций метатезиса
DE69730820D1 (de) Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel
ATE227297T1 (de) 2-pyridylmethylen-polyazamacrocyclophosphonsäur n,ihre komplexe und derivate zur verwendung als kontrastmittel
GR3025447T3 (en) Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide.
BG106390A (en) Novel spiro compounds
EP1304121A4 (de) Inhibitoren der koerpergewichtszunahme
NO972726D0 (no) Tricykliske forbindelser
ATE283867T1 (de) Kontrolle des molekulargewichts in der olefinpolymerisation
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
EP0522841A3 (de) Zersetzung von organischen Hydroperoxiden
BR0315869A (pt) Uso de compostos de complexos de metais como catalisadores de oxidação
AU2003240732A1 (en) Use of transition metal complexes with nitrogen-containing polydentate ligands as a bleaching catalyst and bleaching agent composition
IL125889A0 (en) Bioconjugates of manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
ATE471331T1 (de) Neue übergangsmetall-komplexe und deren einsatz in übergangsmetall-katalysierten reaktionen
NO984165D0 (no) Jernkomplekser av nitrogen-inneholdende makrocykliske ligander effektive som katalysatorer for dismuterende superoksider
WO2002058686A3 (en) Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
DE69912193D1 (de) Substituierte 2-Hydroxybenzophenone, ihre Herstellung, ihre Verwendung als fungizide und ihre fungizide Zusammensetzungen
WO2003059510A3 (en) Manganese(iv) complex salts and their use as oxidation catalysts
NO982240D0 (no) FremgangsmÕte ved oksidering av organiske substrater i nµrvµr av metallkomplekser av tetra-, penta-, og heksakooridinerte ligander, samt oksidasjonskatalysatorer inneholdende disse
ATE344264T1 (de) Porphyrin-verbindung, deren albumin- einschlussverbindung und künstlicher sauerstoffträger

Legal Events

Date Code Title Description
8364 No opposition during term of opposition